Peiyao Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Peiyao Li has a total of 104 co-authors. Here are the top co-authors by number of shared publications:
- Adam Ertel
Sidney Kimmel Cancer Center Thomas Jefferson University, Philadelphia, Pennsylvania
13 shared publications - Carlos Cordon-Cardo
Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
13 shared publications - Daniel Peter Petrylak
Smilow Cancer Center, Yale School of Medicine, New Haven, CT
13 shared publications - Haidong Dong
Mayo Clinic
13 shared publications - Haojie Huang
Department of Biochemistry and Molecular Biology, Mayo Clinic College of Medicine and Science, Rochester, USA
13 shared publications - Josep Domingo-Domenech
Mayo Clinic 1 Department of Biochemistry and Molecular Biology Rochester, Minnesota
13 shared publications
Latest Publications
- Open Access
- 2 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eaeb0821
HLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors
Epitopic peptides presented by class-I human leukocyte antigen (HLA-I) proteins provide the basis of immune surveillance by T cells. Conversely, reduced surface HLA-I expression is a hallmark of immune evasion by latent viral infections and cancer, which confounds the identification of peptide antigens and neoantigens. Here, we outline a system (HLA-Shuttle) for in vitro manipulation of cells with engineered components of the HLA-I processing machinery to confer a continuum of chaperoning activity throughout their trafficking pathway. HLA-Shuttle restores antigen presentation in immunologically cold neuroblastoma cells, enabling identification of multiple tumor-associated antigens with therapeutic potential. Cellular trafficking assays and single-particle tracking reveal a global stabilization of HLA-I molecules, extension of their cell-surface lifetime and microdomain formation. HLA-Shuttle can be used across a range of aberrant cellular states where low antigen expression remains a bottleneck for the identification of endogenous peptide antigens.
- 2 January 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 12 (1) , eaeb0821
Open AccessHLA-Shuttle: A system for enhancing antigen presentation in immunologically cold tumors
Epitopic peptides presented by class-I human leukocyte antigen (HLA-I) proteins provide the basis of immune surveillance by T cells. Conversely, reduced surface HLA-I expression is a hallmark of immune evasion by latent viral infections and cancer, which confounds the identification of peptide antigens and neoantigens. Here, we outline a system (HLA-Shuttle) for in vitro manipulation of cells with engineered components of the HLA-I processing machinery to confer a continuum of chaperoning activity throughout their trafficking pathway. HLA-Shuttle restores antigen presentation in immunologically cold neuroblastoma cells, enabling identification of multiple tumor-associated antigens with therapeutic potential. Cellular trafficking assays and single-particle tracking reveal a global stabilization of HLA-I molecules, extension of their cell-surface lifetime and microdomain formation. HLA-Shuttle can be used across a range of aberrant cellular states where low antigen expression remains a bottleneck for the identification of endogenous peptide antigens.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S2. sPOM121 is associated with transcriptionally active chromatin.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S2. sPOM121 is associated with transcriptionally active chromatin.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S7 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S7. sPOM121 decreases tumor infiltrating CD8+ T lymphocytes and confers poor response to anti-PD-1 therapy.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S7. sPOM121 decreases tumor infiltrating CD8+ T lymphocytes and confers poor response to anti-PD-1 therapy.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors.Significance:This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
The roles of nucleoplasm-residing nucleoporins (NUP) in solid tumors, including prostate cancer, remain unknown. In this study, we reveal the clinical significance and mechanistic role of the off-pore NUP, soluble POM121 (sPOM121), as a crucial transcriptional regulator that enhances the aggressiveness of metastatic prostate cancer. Using orthogonal methodologies in human samples, sPOM121 was identified as the predominantly expressed nucleoplasmic NUP in prostate cancer. Unbiased proteomic and epigenomic studies demonstrate that sPOM121, through its C-terminus, interacts with the chromatin remodeler SMARCA5 at gene promoter sites and localizes at nuclear condensates, reprogramming gene expression. Indeed, sPOM121 regulates a distinct oncogenic gene network, including β-catenin, leading to prostate cancer progression and immune evasion. Importantly, targeting the sPOM121/β-catenin axis in patient-derived preclinical and syngeneic mouse models halts prostate cancer aggressiveness and enhances antitumor immunity. Taken together, these findings reveal previously unknown actionable reprogramming functions of off-pore NUPs in solid tumors.Significance:This study uncovers how oncogenic signaling programs are transcriptionally heightened by the NUP sPOM121 in metastatic prostate cancer. Localization of sPOM121 at active transcriptional nuclear condensates propels disease progression and immune evasion, offering novel anticancer therapeutic opportunities.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Table S2 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Table S2 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S6 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S6. The sPOM121/catenin axis contributes to prostate cancer aggressiveness.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S6. The sPOM121/catenin axis contributes to prostate cancer aggressiveness.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S5. sPOM121/SMARCA5 regulate a discrete gene network.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S5. sPOM121/SMARCA5 regulate a discrete gene network.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S4. sPOM121 C-terminus regulates gene expression.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S4. sPOM121 C-terminus regulates gene expression.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S3. sPOM121 and SMARCA5 localize at specific gene promoters.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Off-pore Nucleoporin sPOM121 Transcriptionally Propels β-Catenin–driven Tumor Progression and Immune Escape in Prostate Cancer
Supplementary Figure S3. sPOM121 and SMARCA5 localize at specific gene promoters.